{"filings":[{"id":1236636,"accession_number":"0001627223-26-000017","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2026-06-24T14:48:32+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Chemours agrees to $22.5M penalty and $90M in PFAS mitigation projects to settle EPA claims","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Civil penalty of $22.5M payable in three annual installments starting within 30 days of court approval; $15M already accrued.","Over 15 years, Chemours will fund $90M in additional mitigation projects to reduce PFAS emissions and expand off-site drinking water programs.","Expansion of drinking water programs in West Virginia, Ohio, and New Jersey; expects increase to environmental reserves.","Also resolved West Virginia Rivers Coalition Clean Water Act litigation for less than $1 million.","Settlement is subject to court approval; no admission of liability by Chemours."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94181,"accession_number":"0001627223-26-000010","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q1 net loss widens to $29M; adjusted EBITDA up 2% to $169M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.381B, up 1% YoY; TSS segment posted record Q1 with double-digit Opteon growth.","Net loss $(29)M ($0.19/sh) vs $(5)M ($0.03/sh) YoY; adjusted net income $8M ($0.05/sh) vs $19M ($0.13/sh).","Adjusted EBITDA $169M (+2% YoY); sequential TiO2 price increased 3% in net sales.","Received ~$287M net from Kuan Yin site sale; used to pay down €140M of debt.","Volume down 4% YoY due to production constraints from an operational outage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1381000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94180,"accession_number":"0001193125-26-193216","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 2026 Equity Plan, elect 11 directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 Equity Plan approved with ~96.7% of votes cast; authorizes 6,375,275 shares for issuance.","All 11 director nominees elected with 95.8% to 99.3% of votes cast for each.","Say-on-pay advisory vote approved with 97.5% of votes cast in favor.","Ratification of PricewaterhouseCoopers LLP as independent auditor approved with 99.4% of votes cast.","Plan replaces 2017 Equity and Incentive Plan; prior awards reduce share reserve on a one-for-one basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106373,"accession_number":"0001627223-26-000002","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","8.01","2.03","9.01"],"status":"ready","headline":"Chemours issues $700M 7.875% senior notes due 2034; refinances 2027 and 2028 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed private offering of $700M aggregate principal of 7.875% senior notes due 2034.","Used net proceeds plus cash to redeem $188M of 5.750% notes due 2028 for ~$189.8M.","Remaining proceeds expected to redeem ~$500.3M of 5.375% notes due 2027.","Notes are unsecured, rank equally with existing unsubordinated debt, mature March 15, 2034.","Interest payable semi-annually on March 15 and September 15, beginning September 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106372,"accession_number":"0001193125-26-077205","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemours prices $700M of 7.875% senior notes due 2034, upsized from $600M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $700M aggregate principal of 7.875% senior unsecured notes due 2034, upsized from $600M.","Interest payable semi-annually beginning Sept 15, 2026; notes mature March 15, 2034.","Proceeds to redeem 5.375% notes due 2027 and partially redeem 5.750% notes due 2028.","Offering expected to close March 12, 2026, subject to customary closing conditions.","Notes offered privately under Rule 144A and Regulation S; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106371,"accession_number":"0001193125-26-059564","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q4 net loss widens to $47M; full year 2026 outlook: Adj. EBITDA $800M-$900M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $47M (-$0.31/diluted) vs loss $11M (-$0.08) YoY; adjusted net income $7M ($0.05) vs $14M ($0.09).","Q4 adjusted EBITDA $128M vs $168M YoY; net sales $1.3B slightly down; TSS segment record Q4 with 37% Opteon revenue growth.","Full year 2025 net loss $386M (-$2.57/diluted) vs net income $69M ($0.46) prior year; adjusted net income $143M ($0.95) vs $179M ($1.19).","Full year 2026 outlook: net sales growth 3-5%, adjusted EBITDA $800-$900M, free cash flow conversion above 25%.","Announced sale of former Kuan Yin TiO2 site for ~$300M net proceeds on Jan 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":5808000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106370,"accession_number":"0001193125-26-014624","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Chemours agrees to sell Taiwan land for $360M, proceeds to reduce debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total gross cash proceeds of approximately $360 million from sale of former TiO2 site in Kuan Yin, Taiwan.","Buyers include Century Wind Power, Century Iron & Steel, and Century Huaxin Wind Energy.","Closings expected by mid-2026, subject to local regulatory and environmental approvals.","Company intends to use proceeds to reduce its debt obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122710,"accession_number":"0001193125-25-269744","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q3 net income $60M vs loss prior year; adjusted EBITDA $195M down 3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $60M ($0.40/share) reverses prior-year loss of $32M; adjusted net income $30M ($0.20) vs $61M.","Revenue $1.5B flat YoY; TSS Opteon refrigerants grew 80% YoY, offset by APM Washington Works outage.","Adjusted EBITDA $195M down 3% YoY; management says consolidated results exceeded expectations.","Announced global TiO2 price increase effective Dec 1, 2025; strategic agreement with SRF Limited in India.","Qualified two-phase immersion cooling fluid with Samsung Electronics for data center applications."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":4478000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122709,"accession_number":"0001193125-25-260863","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemours adopts new executive severance policy with 2.0x multiplier for CEO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO severance: 2.0x sum of base salary, target annual incentive, and annualized health care subsidy; other execs 1.0x.","Payable on involuntary termination without Cause or resignation for Good Reason; requires signed release of claims.","Existing change-in-control agreements and equity award terms remain in effect; policy does not supersede them.","Policy effective October 28, 2025; administered by Board or Compensation Committee; amendment requires 12-month notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122708,"accession_number":"0001193125-25-240643","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Chemours extends $1.05B term loan to 2032 and secures €180M factoring facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $1.05B Term Loan B-3 US$ to Oct 2032 from Aug 2028; margin Term SOFR+3.50%.","Entered €180M receivables factoring agreement with BNP Paribas; initial term to Oct 2026, auto-renewal.","Chemours subsidiaries sell up to €180M eligible receivables; parent guarantees obligations.","Actions improve liquidity and extend debt maturity profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139397,"accession_number":"0000950170-25-112670","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Chemours appoints Mary Cranston as Chair, Alister Cowan as Lead Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board Chair Dawn Farrell departs to lead Canadian government's Major Projects Office under the Building Canada Act.","Mary Cranston appointed as Chair of the Board effective September 2, 2025.","Alister Cowan appointed to the role of Lead Independent Director, effective same date.","Changes follow Farrell's acceptance of CEO position at newly created Major Projects Office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139396,"accession_number":"0001627223-25-000005","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemours Chair Dawn Farrell resigns effective Sept 2 for Canadian government role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chair Dawn Farrell notified Board on Aug 29, 2025 of resignation effective Sept 2, 2025.","Farrell to become CEO of Canada's Major Projects Office under the Building Canada Act.","Successor as Chair not yet named; announcement to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139395,"accession_number":"0000950170-25-103204","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q2 net loss $381M; adjusted EBITDA up 22% to $253M; NJ PFAS settlement reached","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $381M ($2.54 diluted EPS) vs net income $60M ($0.39) in Q2 2024; adjusted net income $87M ($0.58).","Net sales $1.615B, up 4% YoY; TSS Opteon Refrigerants grew 65% year-over-year.","Adjusted EBITDA $253M, up 22% from $207M in prior-year quarter.","Reached comprehensive settlement with New Jersey resolving all statewide PFAS environmental claims.","Declared quarterly cash dividend of $0.0875 per share for Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":2983000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139394,"accession_number":"0001104659-25-073336","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Chemours, DuPont, Corteva agree to $875M NJ PFAS settlement; Chemours share ~$250M PV","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Total $875M cash over 25 years; pre-tax PV ~$500M (8% discount); Chemours 50% (~$250M PV).","DuPont 35.5% (~$177M PV), Corteva 14.5% (~$72M PV); payments start Jan 1, 2026 at earliest.","DuPont and Corteva to buy $150M of Chemours' PFAS insurance rights; Chemours gets 50% of further recoveries.","Chemours expects assigned insurance plus existing restricted cash to fund its obligations through at least 2030.","Settlement resolves all NJ environmental claims including four sites and statewide PFAS; subject to court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156980,"accession_number":"0000950170-25-064539","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q1 net loss of $4M vs profit $54M; adjusted EBITDA $166M; cuts dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4M, diluted EPS -$0.03 vs net income $54M, EPS $0.36 YoY.","Adjusted net income $19M ($0.13 EPS) vs $47M ($0.31 EPS); adjusted EBITDA $166M vs $191M.","Opteon refrigerants net sales up 40% YoY; signed liquid cooling agreement with Navin Fluorine.","Declared reduced Q2 dividend for balance sheet flexibility; returned $37M dividends in Q1.","Restructuring charges incurred from shutdown of APM's SPS Capstone business."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1368000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156979,"accession_number":"0000950170-25-058126","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemours annual meeting: supermajority amendment fails, biodiversity proposal defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected with 92.8%–98.8% FOR.","Advisory say-on-pay passed with 93.8% support.","Ratification of PwC as auditor approved with 98.9% FOR.","Amendment to eliminate supermajority voting provisions failed (75.5%, below 80% threshold).","Shareholder proposal to adopt biodiversity impact policy defeated (6.4% FOR)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175355,"accession_number":"0000950170-25-047846","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemours extends receivables facility maturity to 2028, reduces limit to $165M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity date extended from March 31, 2025 to March 31, 2028.","Facility limit reduced from $175 million to $165 million.","Fourth Amendment executed on March 28, 2025; includes updated fee letter.","No Events of Termination or Unmatured Events of Termination exist before or after amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175354,"accession_number":"0000950170-25-036513","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemours director Guillaume Pepy will not stand for re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pepy notified the board on March 9, 2025 of his decision not to seek re-election.","His current term will expire at the 2025 Annual Meeting of Shareholders.","Pepy stated the decision is not due to any disagreement with company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175353,"accession_number":"0000950170-25-021792","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemours director Curtis Anastasio not seeking re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Curtis V. Anastasio will not stand for re-election to Chemours' Board at the 2025 Annual Meeting.","His decision is not due to any disagreement with the company's operations, policies, or practices.","Anastasio's term will expire at the conclusion of the 2025 Annual Meeting of Stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175352,"accession_number":"0000950170-25-021779","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours reports Q4 2024 net loss of $8M, provides FY2025 EBITDA guidance of $825-975M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 Net Sales $1.4B flat YoY; Net Loss $8M ($0.05 diluted) vs prior year loss $18M.","Q4 Adjusted Net Income $16M ($0.11) down from $46M ($0.31) prior year.","FY2024 Adj. EBITDA $786M, down from $1.0B; FY2025 outlook $825M-$975M.","Fully remediated four material weaknesses in internal control.","TSS segment Q4 record sales; Opteon Refrigerants up 23% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":5782000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175351,"accession_number":"0000950170-25-017985","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Chemours appoints Leslie M. Turner to Board; 2025 annual meeting set for April 22","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leslie M. Turner appointed to Chemours Board effective Feb 19, 2025.","Board expands to 12 members; Turner serves on Nominating/Governance and Compensation Committees.","Turner previously EVP, GC at Hershey; held roles at Coca-Cola and U.S. Interior Dept.","2025 Annual Shareholders Meeting scheduled for April 22, 2025 at 10:00 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175350,"accession_number":"0000950170-25-002553","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemours appoints Google VP Joseph Kava to board, effective Jan 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph D. Kava appointed to Chemours board; board size increased from 10 to 11 members.","Kava is Vice President of Data Centers at Google (NASDAQ: GOOG), with 30 years tech experience.","He will serve on Audit Committee and Nominating and Corporate Governance Committee.","Kava's appointment aligns with Chemours' Pathway to Thrive strategy, especially data center cooling.","No arrangements, family relationships, or reportable transactions with Kava."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192294,"accession_number":"0000950170-24-136240","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Chemours reprices €415M Term Loan B-3; margin cut 75 bps to EURIBOR+3.25%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment reduces applicable margin on Tranche B-3 Euro Term Loan from EURIBOR+4.00% to EURIBOR+3.25%.","Facility principal unchanged at €415M; maturity remains August 2028.","Repricing lowers annual interest cost by roughly €3.1M based on current EURIBOR.","No other changes to terms or covenants; amendment effective December 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192289,"accession_number":"0000950170-24-132273","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K/A","filed_at":"2024-12-02T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Chemours files 8-K/A to correct exhibits for $600M 8.000% Senior Notes due 2033 offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment corrects technical error in Exhibits 4.2 and 4.3 from original 8-K filed November 27, 2024.","No changes to the $600M aggregate principal amount, 8.000% coupon, or 2033 maturity of the notes.","Original disclosure regarding closing of the private offering remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192293,"accession_number":"0000950170-24-131910","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Chemours reprices $1.07B term loan, margin cut by 50 bps","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Margin on Term Loan B-3 US$ Facility reduced from SOFR+3.50% to SOFR+3.00% (or base rate+2.50% to +2.00%).","Principal amount remains $1,070,000,000; maturity unchanged at August 2028.","Amendment dated Nov 29, 2024; JPMorgan Chase Bank remains administrative agent.","All other terms substantially unchanged from existing Second Amended and Restated Credit Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192292,"accession_number":"0000950170-24-131547","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","8.01","2.03","9.01"],"status":"ready","headline":"Chemours closes $600M 8% senior notes due 2033, to redeem €441M 4% notes due 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M aggregate principal of 8.000% Senior Notes due January 15, 2033 in a private offering.","Net proceeds to redeem all outstanding €440.81M of 4.000% Senior Notes due 2026 plus accrued interest.","Notes are senior unsecured obligations guaranteed by certain subsidiaries; interest payable semi-annually on Jan 15 and Jul 15 starting Jul 15, 2025.","Redemption prior to Jan 15, 2028 at make-whole premium; up to 40% redeemable at 108% with equity offering proceeds.","Change of control puts at 101% plus accrued interest; customary negative covenants and event of default provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192291,"accession_number":"0000950170-24-126406","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemours prices $600M 8% senior notes due 2033 to refinance 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M principal of 8.000% senior unsecured notes due 2033 priced in private offering.","Net proceeds to redeem all outstanding €440.81M 4% notes due 2026; remainder for general corporate purposes.","Notes guaranteed by certain subsidiaries; expected to close Nov 27, 2024.","Interest payable semi-annually beginning July 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192290,"accession_number":"0000950170-24-120258","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q3 net loss $27M on $56M impairment; adjusted EPS $0.40; TSS Opteon sales up 21%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27M ($0.18/diluted share) due to $56M non-cash impairment of APM goodwill.","Net sales $1.5B (+1% YoY); TSS record sales with Opteon refrigerants up 21% YoY.","Adjusted EBITDA $208M vs $211M; TT segment Adjusted EBITDA up 23% YoY.","Cash returned $38M in dividends; refreshed corporate strategy designed for sustainable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":4388000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208784,"accession_number":"0000950170-24-096636","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemours posts August 2024 investor presentation on its website; specific content not disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated August 2024 filed as Exhibit 99.1; no financial or strategic details extracted from text.","Company will use presentation for upcoming meetings with investors, analysts, and other parties.","No material changes or guidance updates are evident from the exhibit title alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208783,"accession_number":"0000950170-24-089310","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q2 net income $70M vs prior loss; adj EBITDA down 36%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.5B (-6% YoY); net income $70M ($0.46 diluted EPS) vs prior-year net loss $376M ($2.52 loss).","Adjusted net income $57M ($0.38 diluted) and adjusted EBITDA $206M vs $324M in Q2 2023.","Cash from ops -$620M includes $606M from restricted cash used for U.S. Water District Settlement (now complete).","Received permit to expand Teflon™ PFA resin production for semiconductor manufacturing at APM.","Appointed Shane Hostetter as new CFO, enhancing leadership with capital allocation expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":2887000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208782,"accession_number":"0000950170-24-086564","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemours appoints David A. Will as Controller and Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David A. Will appointed Controller and CAO effective August 12, 2024.","Will previously served as Interim CFO of Copeland LP and VP Global Controller.","Annual base salary of $410,000, signing bonus of $325,000, target bonus 50% of salary.","One-time RSU grant of $125,000 prorated 2024 LTI; additional RSUs and cash to offset lost compensation.","Shane Hostetter remains principal accounting officer until Will's effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226532,"accession_number":"0000950170-24-073084","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemours appoints Tony Satterthwaite as independent director, effective June 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Satterthwaite appointed to Chemours Board, effective June 12; board size increased from 9 to 10 directors.","Satterthwaite is SVP at Cummins (CMI) leading Information Technology and Digital; will retire from Cummins in September 2024.","He serves on Compensation and Leadership Development Committee and Environmental, Health, Safety & Operational Performance Committee.","Satterthwaite also serves on boards of IDEX Corp (IEX), National Association of Manufacturers, and Cummins Foundation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226531,"accession_number":"0000950170-24-069063","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemours names Shane Hostetter as CFO effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hostetter joins from Quaker Houghton, where he served as CFO since April 2021.","He receives $600k base salary, $50k signing bonus, 75% target bonus, $1M LTI target.","One-time grant of $500k RSUs vesting one-third per year over three years.","Interim CFO Matt Abbott returns to role of SVP & Chief Enterprise Transformation Officer.","Hostetter will lead Finance, IR, Corporate Development, Strategy, and Enterprise Risk Management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226530,"accession_number":"0000950170-24-067646","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemours pauses TiO2 production at Altamira, Mexico due to severe drought and government water request","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paused production at Altamira TiO2 facility in Mexico due to severe regional drought.","Complying with government request to temporarily minimize water intake for community conservation.","Cannot predict duration of pause due to factors outside its control; will serve customers via other assets.","Working with government, business, and community partners on short- and long-term solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226529,"accession_number":"0000950170-24-063967","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemours shareholders elect all nine director nominees, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with 91.6% to 97.0% of votes cast in favor.","Advisory say-on-pay vote approved with 94.5% of votes cast in favor.","Ratification of PricewaterhouseCoopers as auditor approved with 97.9% of votes cast.","Broker non-votes totaled 16.05M for director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226528,"accession_number":"0000950170-24-050569","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q1 earnings: net sales $1.35B (-12% YoY), net income $52M, adj EBITDA $193M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.35B, down 12% YoY; volumes -6%, price -5%.","Net income attributable to Chemours $52M ($0.34 per diluted share) vs $145M ($0.96) in Q1 2023.","Adjusted EBITDA $193M vs $304M (-37%).","Cash flows used in operations -$290M; capex $102M; dividends $37M.","Segment declines: APM -23%, TT -7%, TSS -8%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1350000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226527,"accession_number":"0001193125-24-114364","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemours CFO Lock resigns amid accounting review; gets extended options, no severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resigned as SVP & CFO effective April 23, 2024; no severance, no 2023 or 2024 annual incentive.","Vested stock options on ~89,184 shares (8 grants, strike $14.43-$48.25) extended to 3-year exercise window.","Must cooperate with board's ongoing review of accounting matters; breach may forfeit equity awards and require repayment.","Only cash benefit is $7,245 for 3 months COBRA premiums; all unvested equity awards forfeited for no consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245536,"accession_number":"0001193125-24-081149","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemours files transcript of Q4 and FY2023 earnings call; no specific results in 8-K","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing furnishes transcript of March 28, 2024 earnings call discussing Q4 and full year 2023 results.","No financial figures, guidance, or segment data are included in the 8-K filing or summary exhibit.","Investors must listen to or read the full transcript for actual performance details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245535,"accession_number":"0000950170-24-037416","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemours reveals ~$100M Q4 pay delay, ~$260M early receivables; 4 material weaknesses found","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee review found Q4 2023 vendor payments of up to ~$100M delayed into Q1 2024.","Collection of ~$260M receivables originally due Q1 2024 accelerated into Q4 2023.","Similar actions in Q4 2022: delayed ~$40M payments, accelerated ~$175M receivables.","Three former senior management lacked board transparency; compensation committee used full negative discretion on their awards.","Four material weaknesses in internal controls identified; no material misstatement but immaterial revisions to prior financials; remediation plan in progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245534,"accession_number":"0000950170-24-037412","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours Q4 adjusted EPS $0.31 vs $0.00 YoY; full year net loss $238M on $764M litigation charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net sales $1.4B (+2% YoY); full year net sales $6.0B (-11% YoY).","Q4 net loss $18M ($0.12 loss/diluted); adjusted net income $46M ($0.31 diluted EPS).","Full year net loss $238M ($1.60 loss/share); adjusted net income $425M ($2.82 EPS) vs $738M prior.","Adjusted EBITDA Q4 $176M vs $120M prior; full year $1.0B vs $1.4B, impacted by $89M/$764M litigation charges.","Segment: TT +7%, TSS +17%, APM -15%; CEO cites destocking and progress on legacy environmental matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245533,"accession_number":"0001193125-24-077725","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemours schedules Q4/FY23 earnings release for March 27, conference call March 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to issue Q4 and full-year 2023 financial results after market close on March 27, 2024.","Annual Report on Form 10-K for year ended December 31, 2023 also to be filed March 27.","Conference call to discuss results at 8:00 a.m. EDT on March 28, 2024; webcast on investors.chemours.com.","Interim CFO Matthew Abbott signed the filing; no financial results disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245532,"accession_number":"0001193125-24-075860","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemours appoints Denise Dignam as President and CEO, replacing Mark Newman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Denise Dignam named President and CEO effective March 22, 2024; she was interim CEO since February 2024.","Mark Newman resigned as officer and director; separation agreement grants extended stock option exercise period but no severance.","Dignam's compensation: $975k base salary, 120% target bonus, $4.355M LTI award.","Matthew Abbott continues as interim CFO; search for permanent CFO underway.","Diane Iuliano Picho named interim President, Titanium Technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245531,"accession_number":"0001193125-24-070332","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Chemours receives NYSE noncompliance notice for delayed 10-K filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE notified Chemours on March 18, 2024 that it is not in compliance with Section 802.01E for failure to timely file its 2023 Form 10-K.","Company has six months from March 15, 2024 to file the 10-K and regain compliance with NYSE listing standards.","Delay due to additional time needed for year-end reporting process and review of internal control over financial reporting as of Dec 31, 2023.","Previously disclosed internal review by Audit Committee has been substantially completed.","Chemours expects to file the 10-K as promptly as practicable and will schedule Q4/full-year 2023 earnings call separately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245530,"accession_number":"0001193125-24-061056","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemours: senior management delayed payables, accelerated receivables to meet cash targets; material weaknesses expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Senior management placed on administrative leave for delaying vendor payments from Q4 2023 to Q1 2024 and accelerating receivables into Q4 2023 to meet free cash flow targets.","Audit Committee found violations of Code of Ethics for lack of transparency with Board; similar but lesser actions taken in Q4 2022.","Preliminary FY2023 unaudited results unaffected; cash and equivalents $1.8B ($1.2B unrestricted) as of Dec 31, 2023.","Company expects to report material weaknesses in internal control over financial reporting as of Dec 31, 2023, including tone at the top and hotline controls.","Anonymous hotline report not escalated to General Counsel or Audit Committee until year-end external audit process; inadequate controls identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245529,"accession_number":"0001193125-24-051940","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemours places CEO and CFO on leave; internal review finds potential material weaknesses; delays 10-K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Mark Newman, CFO Jonathan Lock, Controller Camela Wisel placed on administrative leave pending internal review.","Interim CEO Denise Dignam appointed; Interim CFO Matt Abbott appointed.","Internal review includes ethics hotline, working capital practices, non-GAAP metrics; evaluating potential material weaknesses in internal control.","Company delays Q4 2023 earnings release and 10-K filing; will file NT 12b-25.","Preliminary 2023 net sales ~$6.0B (down 12% YoY); net loss $225-235M vs $578M net income in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245528,"accession_number":"0001193125-24-051931","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemours places CEO, CFO, and CAO on leave; appoints interim leaders","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Mark Newman, CFO Jonathan Lock, and CAO Camela Wisel placed on administrative leave pending Audit Committee review.","Denise Dignam, President of Titanium Technologies, appointed Interim CEO effective Feb 28, 2024.","Matthew Abbott, SVP & Chief Enterprise Transformation Officer, appointed Interim CFO.","Administrative leave relates to ongoing Audit Committee review of preliminary 2023 financial estimates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245527,"accession_number":"0000950170-24-016376","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemours appoints Pamela Fletcher to board; Sandra Phillips Rogers not standing for reelection","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra P. Rogers will not seek reelection at 2024 annual meeting; decision not due to any disagreement with company.","Pamela F. Fletcher appointed as director effective March 1, 2024; board expands from 9 to 10 members.","Fletcher appointed to Compensation and Leadership Development Committee and Nominating and Corporate Governance Committee.","Fletcher previously served as Delta Airlines CSO and GM Vice President; receives standard director compensation ($105k cash, $160k equity)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245525,"accession_number":"0000950170-24-016384","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K/A","filed_at":"2024-02-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemours names Alister Cowan to Audit and new EHS committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alister Cowan appointed to Audit Committee and the newly formed Environmental, Health, Safety & Operational Performance Committee (formed Feb 12, 2024).","Board determined Cowan is independent and an audit committee financial expert under NYSE and SEC rules.","The new committee will oversee Chemours' environment, health, safety and operational performance initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245526,"accession_number":"0000950170-24-014589","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemours reschedules Q4/FY 2023 earnings; cites internal control evaluation and Audit Committee review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Earnings release postponed from Feb 14 to Feb 28, 2024; conference call moved to Feb 29.","Company needs extra time to complete year-end reporting; evaluating internal controls over financial reporting.","Audit Committee conducting an internal review related to information and communications.","Annual Report on Form 10-K expected to be filed by Feb 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263003,"accession_number":"0000950170-23-066546","cik":1627223,"company_name":"Chemours Co","ticker":"CC","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemours agrees to $110M PFAS settlement with Ohio; records $67.5M pre-tax charge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Chemours, DuPont, and Corteva settle Ohio PFAS claims for $110M; Chemours share $55M.","Chemours records $67.5M pre-tax charge in FY2023, including $12.5M supplemental payment to Delaware trust.","80% of settlement allocated to Washington Works discharges; 20% for other PFAS and AFFF claims.","Settlement subject to court approval; payment due within 10 business days after final court approval.","Consistent with Jan 2021 MOU, Chemours bears 50% of settlement costs, with DuPont and Corteva covering the rest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3427859689.736,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-29T23:59:59+00:00|263003"}